MUC13 Antibody

What is MUC13 and why is it important in cancer research?

MUC13 is a transmembrane glycoprotein that belongs to the mucin family and is normally expressed in epithelial tissues including the large intestine, trachea, kidney, small intestine, and gastric epithelium . It has gained significant research interest due to its overexpression in multiple cancers including pancreatic, colorectal, liver, and ovarian cancers . MUC13 plays a critical role in tumorigenesis by enhancing cell motility, invasion, proliferation, and anchorage-independent growth while decreasing cell-cell and cell-substratum adhesion . Recent studies have demonstrated that MUC13 drives cancer aggressiveness and metastasis through interaction with YAP1 and its nuclear translocation . This makes MUC13 not only a potential biomarker for cancer progression but also a promising therapeutic target.

MUC13 antibodies are utilized in several standard laboratory techniques:

• Western Blotting (WB): For detecting MUC13 protein in cell or tissue lysates. Typically observed molecular weights range from 55-175 kDa, with common bands at 70-90 kDa and 120-175 kDa due to glycosylation .

• Immunohistochemistry (IHC): For visualizing MUC13 expression patterns in tissue sections, particularly useful for comparing normal versus cancer tissues .

• Immunofluorescence (IF): For examining subcellular localization of MUC13, which can inform on its membrane expression and potential internalization patterns .

• ELISA: For quantitative measurement of MUC13 levels in biological samples .

• Immunoprecipitation (IP): For studying MUC13 protein interactions with other cellular components .

What are the optimal conditions for using MUC13 antibodies in Western blotting?

For optimal Western blot results with MUC13 antibodies:

• Sample preparation: Complete lysis buffers containing protease inhibitors are essential as MUC13 can be susceptible to degradation.

• Dilution ratios:

  • Polyclonal antibodies: 1:500-1:3000

  • Monoclonal antibodies: 1:1000

• Molecular weight considerations: MUC13 typically appears between 70-120 kDa in most cell lines, though can range from 55-175 kDa depending on glycosylation status .

• Positive controls: HCT 116, HEK-293, HT-29, or SW480 cells consistently express detectable levels of MUC13 and serve as reliable positive controls .

• Detection systems: Enhanced chemiluminescence (ECL) systems are generally sufficient, though near-infrared fluorescent secondary antibodies may provide better quantification.

What antigen retrieval methods are recommended for MUC13 immunohistochemistry?

Effective antigen retrieval is critical for MUC13 detection in formalin-fixed, paraffin-embedded (FFPE) tissues:

• Primary recommendation: TE buffer at pH 9.0 provides optimal antigen retrieval for most MUC13 antibodies .

• Alternative method: Citrate buffer at pH 6.0 can also be effective, though possibly with reduced signal intensity compared to TE buffer .

• Protocol parameters:

  • Heat-induced epitope retrieval (HIER) using a pressure cooker or microwave

  • 20-30 minutes incubation time

  • Cooling to room temperature before primary antibody application

• Antibody dilutions for IHC:

  • Polyclonal antibodies: 1:500-1:2000

  • Monoclonal antibodies: 1:50

• Detection systems: 3,3'-Diaminobenzidine (DAB) provides consistent results for visualization of MUC13 expression in tissues.

How should MUC13 antibodies be stored to maintain optimal activity?

Proper storage conditions are essential for maintaining antibody functionality:

• Temperature: Store at -20°C for long-term stability .

• Format considerations:

  • Aliquoting is often unnecessary for -20°C storage of smaller volumes (≤20μl)

  • Larger volumes should be aliquoted to avoid repeated freeze-thaw cycles

• Buffer composition: Most commercial MUC13 antibodies are provided in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 .

• Stability: When properly stored, MUC13 antibodies typically remain stable for one year after shipment .

• Special formulations: Some preparations may contain 0.1% BSA as a stabilizer .

How can MUC13 antibodies be used to study cancer progression mechanisms?

MUC13 antibodies enable sophisticated investigations into cancer biology:

• Differential expression analysis: MUC13 antibodies can reveal expression patterns across cancer progression stages, with quantitative analysis showing marked increases in MUC13 expression in advanced tumor stages compared to normal tissue controls .

• Signaling pathway investigations: MUC13 antibodies help elucidate how this protein influences oncogenic signaling, including:

  • HER2, PAK1, and ERK pathway activation

  • YAP1 interaction and nuclear translocation

  • Akt signaling and metastasin (S100A4) upregulation

  • p53 suppression mechanisms

• Localization studies: Immunofluorescence with MUC13 antibodies can reveal specific subcellular localization patterns that inform on tumor cell interactions and signaling functions .

• In vivo models: MUC13 antibodies are essential for validating xenograft models where MUC13 levels correlate with increased tumor burden and metastasis .

What methodological approaches are used to develop and validate novel MUC13 antibodies?

Development of new MUC13 antibodies involves several sophisticated techniques:

• Hybridoma technology workflow:

  • Mouse immunization with recombinant MUC13 protein

  • Fusion of splenocytes with myeloma cells to create hybridomas

  • Selection of positive clones through ELISA screening

  • Purification via NGC liquid chromatography

• Validation methods:

  • Western blot analysis to confirm specific binding and appropriate molecular weight

  • Immunofluorescence to verify cellular localization patterns

  • Immunohistochemistry in patient tissue samples to confirm clinical relevance

  • Comparison across multiple cancer and normal tissue types

• Specificity testing:

  • Use of MUC13 knockout or knockdown cell lines as negative controls

  • Testing across species (human, mouse, rat) to determine cross-reactivity

  • Peptide competition assays to confirm epitope specificity

How can MUC13 antibodies facilitate studies of anoikis resistance in cancer metastasis?

MUC13 antibodies are instrumental in investigating anchorage-independent survival mechanisms:

• Experimental approaches:

  • Detection of MUC13 expression during anoikis induction on poly-HEMA plates

  • Monitoring expression changes in 3D culture models that mimic micrometastasis

  • Analysis of MUC13's relationship to apoptotic markers (Bcl2, cleaved caspase 3)

• Functional correlations:

  • MUC13 expression levels correlate with spheroid size and cell survival in 3D cultures

  • Western blot analysis reveals gradual increase in MUC13 during anchorage-independent conditions in MUC13-overexpressing cells

  • Flow cytometry with MUC13 antibodies helps quantify apoptotic cell populations (Sub G0) during anoikis resistance

• Mechanistic insights:

  • MUC13 antibodies help establish the correlation between MUC13 expression and YAP1 nuclear translocation

  • Immunofluorescence co-localization studies reveal MUC13's interaction with survival pathway components

What are common challenges in detecting MUC13 in experimental systems and how can they be overcome?

Researchers frequently encounter several technical challenges when working with MUC13 antibodies:

How can researchers distinguish between specific and non-specific binding of MUC13 antibodies?

Validating antibody specificity is crucial for reliable research outcomes:

• Control experiments:

  • Use MUC13 knockdown cell lines (e.g., SW620+shMUC13) as negative controls

  • Include isotype controls to account for non-specific binding

  • Perform peptide competition assays using the immunizing peptide

• Cross-validation approaches:

  • Compare results from multiple MUC13 antibodies targeting different epitopes

  • Validate protein expression with mRNA levels using RT-PCR

  • Confirm specificity across multiple experimental techniques (WB, IHC, IF)

• Technical considerations:

  • For Western blotting, pre-absorb antibodies with non-specific proteins

  • For IHC/IF, increase washing steps and optimize blocking conditions

  • Consider specialized blocking agents for tissues with high endogenous biotin

What methodological considerations are important when studying MUC13 in different cancer types?

Cancer-specific adaptations are necessary when studying MUC13 across different malignancies:

• Pancreatic cancer:

  • Well or moderately differentiated adenocarcinomas express MUC13 at higher levels than poorly differentiated types

  • Recommended antibody dilution: 1:500 for IHC in pancreatic tissues

  • Positive control: TCC-PAN2 pancreatic carcinoma cell line

• Colorectal cancer:

  • MUC13 expression correlates with YAP1 nuclear localization

  • SW480 cells (low MUC13) and SW620 cells (high MUC13) serve as comparative models

  • 3D culture systems better replicate in vivo MUC13 functions than 2D cultures

• Ovarian cancer:

  • MUC13 expression varies significantly between histological subtypes

  • Modified antigen retrieval (extended time in citrate buffer) may be necessary

  • Co-staining with CA125 helps differentiate MUC13-specific signals

How might MUC13 antibodies be utilized in developing targeted cancer therapies?

MUC13 antibodies show promise for therapeutic development:

• Antibody-drug conjugates (ADCs):

  • MUC13 antibodies can be conjugated to potent anti-cancer drugs

  • Internalization properties of antibodies like TCC56 make them suitable for ADC development

  • Targeting apical antigens like MUC13 has shown clinical promise in other cancer types

• Immunotherapy approaches:

  • MUC13 antibodies could block oncogenic signaling pathways

  • Potential for combining with immune checkpoint inhibitors

  • Development of bispecific antibodies targeting MUC13 and immune effector cells

• Nanoparticle vaccines:

  • MUC13 antibodies can help in developing nanoparticle-based vaccines

  • These vaccines may boost immune responses against MUC13-expressing tumors

What methodological advances are needed to better understand MUC13's role in cancer metastasis?

Future research will require sophisticated methodological approaches:

• Advanced imaging techniques:

  • Live-cell imaging with fluorescently tagged MUC13 antibodies

  • Super-resolution microscopy to study MUC13 clustering and interactions

  • Intravital microscopy to track MUC13-expressing cells during metastasis in vivo

• Multi-omics integration:

  • Combining antibody-based proteomics with transcriptomics and metabolomics

  • Correlation of MUC13 expression with global phosphoproteome changes

  • Single-cell analysis of MUC13 expression heterogeneity within tumors

• Model systems development:

  • Generation of conditional MUC13 knockout mouse models

  • Patient-derived organoids for evaluating MUC13 targeting strategies

  • Microfluidic systems to study MUC13's role in circulating tumor cells

How can researchers reconcile contradictory findings about MUC13 expression patterns across different studies?

Addressing research discrepancies requires methodological rigor:

• Standardization approaches:

  • Establish reference standards for MUC13 quantification

  • Create detailed protocols for tissue processing and antibody application

  • Develop consensus guidelines for interpreting MUC13 expression patterns

• Technical considerations:

  • Account for antibody clone-specific differences in epitope recognition

  • Consider glycosylation status variations across tissue types

  • Standardize scoring systems for MUC13 positivity in IHC

• Contextual factors:

  • Integrate clinical data with experimental findings

  • Consider tumor microenvironment influence on MUC13 expression

  • Account for treatment history in patient samples when analyzing MUC13 patterns